| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥369M | ¥422M | -12.6% |
| Cost of Sales | ¥166M | ¥203M | -18.4% |
| Gross Profit | ¥204M | ¥220M | -7.0% |
| SG&A Expenses | ¥1.01B | ¥1.14B | -11.5% |
| Operating Income | ¥-805M | ¥-920M | +12.5% |
| Non-operating Income | ¥2M | ¥22M | -88.5% |
| Non-operating Expenses | ¥5M | ¥15M | -69.8% |
| Ordinary Income | ¥-807M | ¥-914M | +11.7% |
| Profit Before Tax | ¥-798M | ¥-913M | +12.6% |
| Income Tax Expense | ¥2M | ¥3M | -5.7% |
| Net Income | ¥-800M | ¥-915M | +12.6% |
| Interest Expense | ¥3M | ¥2M | +42.5% |
| Basic EPS | ¥-11.79 | ¥-16.26 | +27.5% |
| Dividend Per Share | ¥0.00 | ¥0.00 | - |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥1.36B | ¥2.34B | ¥-975M |
| Cash and Deposits | ¥1.01B | ¥2.06B | ¥-1.06B |
| Accounts Receivable | ¥47M | ¥51M | ¥-4M |
| Inventories | ¥53M | ¥46M | +¥7M |
| Non-current Assets | ¥187M | ¥131M | +¥56M |
| Item | Value |
|---|---|
| Net Profit Margin | -216.8% |
| Gross Profit Margin | 55.3% |
| Current Ratio | 558.6% |
| Quick Ratio | 536.8% |
| Debt-to-Equity Ratio | 0.24x |
| Interest Coverage Ratio | -277.68x |
| Effective Tax Rate | -0.3% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | -12.5% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 68.05M shares |
| Treasury Stock | 12K shares |
| Average Shares Outstanding | 67.85M shares |
| Book Value Per Share | ¥18.37 |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥0.00 |
| Year-End Dividend | ¥0.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| DrugDiscoveryAndDevelopment | ¥3M | ¥-586M |
| DrugDiscoverySupport | ¥370M | ¥204M |
| Item | Forecast |
|---|---|
| Dividend Per Share Forecast | ¥0.00 |
| Property, Plant & Equipment | ¥39M | ¥0 | +¥39M |
| Total Assets | ¥1.55B | ¥2.47B | ¥-919M |
| Current Liabilities | ¥244M | ¥493M | ¥-250M |
| Accounts Payable | ¥35M | ¥27M | +¥8M |
| Short-term Loans | ¥79M | ¥282M | ¥-202M |
| Non-current Liabilities | ¥55M | ¥55M | +¥326,000 |
| Total Liabilities | ¥299M | ¥549M | ¥-249M |
| Total Equity | ¥1.25B | ¥1.92B | ¥-670M |
| Capital Stock | ¥1.07B | ¥996M | +¥70M |
| Capital Surplus | ¥2.01B | ¥1.94B | +¥70M |
| Retained Earnings | ¥-1.82B | ¥-1.02B | ¥-800M |
| Treasury Stock | ¥-292,000 | ¥-292,000 | ¥0 |
| Owners' Equity | ¥1.25B | ¥1.91B | ¥-660M |
| Working Capital | ¥1.12B | - | - |